DGAP-News

ERYTECH Completes Patient Enrollment in Phase 2 Trial of eryaspase (GRASPA(R)) for Pancreatic Cancer - Seite 2

depletion, allowing it to potentially have an impact.

About ERYTECH and ERY-ASP (GRASPA(R)): www.erytech.com

Founded in Lyon, France in 2004, ERYTECH is a clinical-stage
biopharmaceutical company developing innovative therapies for rare forms of
cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform,
which uses a novel technology to encapsulate therapeutic drug substances
inside red blood cells, ERYTECH has developed a pipeline of product
candidates targeting markets with high unmet medical needs. ERYTECH's
initial focus is on the treatment of blood cancers, including acute
lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), by depriving
tumors of nutrients necessary for their survival. ERYTECH has recently
filed for European Marketing Authorization for its lead product candidate,
eryaspase, also known as ERY-ASP or under the trade name GRASPA(R),
following positive efficacy and safety results from its completed Phase 2/3
pivotal clinical trial in Europe in children and adults with relapsed or
refractory ALL. ERYTECH also has an ongoing Phase 1 clinical trial of
eryaspase in the United States in adults with newly diagnosed ALL, and a
Phase 2b clinical trial in Europe in elderly patients with newly diagnosed
AML, each in combination with chemotherapy.

Eryaspase consists of an enzyme, L-asparaginase, encapsulated inside donor-
derived red blood cells. L-asparaginase depletes asparagine, a naturally
occurring amino acid essential for the survival and proliferation of cancer
cells, from circulating blood plasma. Every year over 50,000 patients in
Europe and the United States are diagnosed with ALL or 2

AML. For about 80% of these patients, mainly adults and relapsing patients,
current forms of L-asparaginase cannot be used due to their toxicity or as
a result of allergic reactions. ERYTECH believes that the safety and
efficacy profile of eryaspase (GRASPA(R)), as observed in its Phase 2/3
pivotal clinical trial, offers an attractive alternative option for the
treatment of leukemia patients.

ERYTECH believes that eryaspase has the potential as a treatment approach
in solid tumors and is conducting a Phase 2 clinical trial in Europe in
patients with metastatic pancreatic cancer.

In addition to its current product candidates that focus on using
encapsulated enzymes to induce tumor starvation, ERYTECH is exploring the
use of its platform for developing cancer vaccines and enzyme replacement
therapies.

The EMA and the U.S. Food and Drug Administration (FDA) have granted orphan
drug designations for eryaspase for the treatment of ALL, AML and
pancreatic cancer. ERYTECH produces eryaspase at its own GMP-approved and